WS-12, QX-314, allyl isothiocyanate, cinnamaldehyde, and capsaicin were purchased from Sigma Aldrich. Artemin was purchased from R&D Systems, CGRP(8–37) receptor antagonist from Tocris, TRPM8 antagonist PBMC from Focus Biomolecules, and TLR4 antagonist TAK-242 from Calbiochem.
Ethanol was used as vehicle throughout this study except for injections of CGRP(8–37), TAK-242 and Artemin in which 0.9% saline was used as the vehicle. All injections were at a volume of 20μl and intraplantar in one hind paw for all experiments, except for Cold Plate where both fore paws were injected with 10μl, as previously described [30 (link); 39 (link)]. Amounts injected of each chemical were: cinnamaldehyde 120ng and 50μg, capsaicin 1μg, allyl isothiocyanate 0.15%, CGRP(8–37) 6.4mmol, TAK-242 0.2μg, WS-12 20μg, PBMC 100μg, Artemin 0.2μg, and QX-314 1%.
Ethanol was used as vehicle throughout this study except for injections of CGRP(8–37), TAK-242 and Artemin in which 0.9% saline was used as the vehicle. All injections were at a volume of 20μl and intraplantar in one hind paw for all experiments, except for Cold Plate where both fore paws were injected with 10μl, as previously described [30 (link); 39 (link)]. Amounts injected of each chemical were: cinnamaldehyde 120ng and 50μg, capsaicin 1μg, allyl isothiocyanate 0.15%, CGRP(8–37) 6.4mmol, TAK-242 0.2μg, WS-12 20μg, PBMC 100μg, Artemin 0.2μg, and QX-314 1%.
